NKX3.1 immunoreactivity is not identified in mesenchymal chondrosarcoma: a 25‐case cohort study
- 11 August 2020
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 78 (2) , 334-337
Abstract
Aims: Mesenchymal chondrosarcoma (MC) is characterised typically by a bimorphic microscopic appearance of islands of a well‐differentiated cartilaginous component, admixed with a primitive small cell component, which commonly expresses CD99 and NKX2.2. Given the variable relative abundance of each component and histological overlap with other small round cell tumours, the diagnosis can be challenging, especially in a limited sample. A distinctive gene fusion between HEY1 (located in 8q21) and NCOA2 (located in 8q13) was identified in MC, but the downstream molecular events are unknown. NKX3.1 (coding gene located in 8p21.1) was recently reported to be expressed in a small number of MC cases. The purpose of this study was to evaluate the potential diagnostic utility of NKX3.1 immunohistochemistry in MC.Methods and results: We evaluated sections from 25 cases of MC, including 20 extraskeletal and five osseous. The tumour affected nine females and 16 males, with a median age of 34 years (age range = 7–82 years). Two different rabbit antibodies against NKX3.1 (monoclonal and polyclonal) were used for immunohistochemistry. However, no immunoreactivity was observed with either of the antibodies in all 25 (100%) MC.Conclusions: NKX3.1 immunoreactivity was not identified in our cohort. Clonality of the antibody could not explain the negativity.Keywords
This publication has 13 references indexed in Scilit:
- NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal ChondrosarcomaAmerican Journal of Surgical Pathology, 2020
- Primary adenocarcinoma of the trachea revealing a mucinous bronchial gland cell originPathology - Research and Practice, 2018
- Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER DatabaseClinical Orthopaedics and Related Research, 2017
- Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society studyEuropean Journal of Cancer, 2015
- Best Practices Recommendations in the Application of Immunohistochemistry in the ProstateAmerican Journal of Surgical Pathology, 2014
- Identification of a novel, recurrent HEY1‐NCOA2 fusion in mesenchymal chondrosarcoma based on a genome‐wide screen of exon‐level expression dataGenes, Chromosomes and Cancer, 2011
- NKX3.1 as a Marker of Prostatic Origin in Metastatic TumorsAmerican Journal of Surgical Pathology, 2010
- A luminal epithelial stem cell that is a cell of origin for prostate cancerNature, 2009
- Roles for Nkx3.1 in prostate development and cancerGenes & Development, 1999
- Unusual benign and malignant chondroid tumors of bone.A survey of some mesenchymal cartilage tumors and malignant chondroblastic tumors, including a few multicentric ones, as well as many atypical benign chondroblastomas and chondromyxoid fibromasCancer, 1959